Foretinib is primarily used in clinical research as an investigational drug targeting various types of cancers. It functions as a dual inhibitor of MET and VEGFR2 kinases, which are critical in tumor growth and angiogenesis. This makes it particularly relevant in studying cancers such as hepatocellular carcinoma, gastric cancer, and non-small cell lung cancer, where these pathways are often dysregulated. Foretinib has been explored in phase I and II trials to assess its efficacy in inhibiting tumor progression and metastasis. Additionally, it is being investigated for its potential to overcome resistance to other targeted therapies, offering a promising avenue for combination treatments in oncology research.